皮肤活检可增强对弥漫性皮肤型系统性硬化症临床轨迹的预测
研究分析了参与来那度胺、贝利木单抗或尼洛替尼试验的弥漫性皮肤型系统性硬化症患者的皮肤活检与临床数据,评估成纤维细胞CD34、α-SMA及免疫细胞浸润与疾病病程的关系并识别改善预测因子。在68例霉酚酸酯使用者中建立了临床改善的优化多元逻辑回归模型。皮肤活检可能有助于细化预后和指导患者管理决策。
要点
- 早期疾病(<18个月)与较低的CD34、较高的α-SMA、增多的B细胞及更大的mRSS改善相关。
- 在霉酚酸酯使用者中,高CD34和高α-SMA预测早期SSc的改善;但在晚期SSc中,高α-SMA预测改善几率较低。
- 早期SSc中α-SMA低/CD34低免疫表型及晚期SSc中α-SMA高者改善概率最低。
核心结论
- 成纤维细胞免疫表型随基线疾病病程变化,并提高了识别霉酚酸酯治疗改善者的模型性能。
- 皮肤活检可能有助于细化预后和指导患者管理决策。
研究设计与样本
- 分析参与来那度胺(n=79)、贝利木单抗(n=18)或尼洛替尼(n=8)试验的弥漫性皮肤型系统性硬化症患者的皮肤活检和临床数据。
- CD34和α-SMA采用半定量评分,计数免疫细胞(CD20+、CD3+、CD123+)。
- 比较早期(<18个月)与晚期(≥18个月)疾病的临床和组织学特征。
- 临床改善定义为52周时改良Rodnan皮肤评分(mRSS)下降>5分。
- 在68例霉酚酸酯使用者中建立Akaike信息准则最优的多元逻辑回归模型。
主要发现
- 尽管基线mRSS相似,早期疾病与较低的CD34、较高的α-SMA、增多的B细胞及更大的mRSS改善相关(与晚期SSc相比)。
- IMC显示CD34+成纤维细胞位于真皮浅层,α-SMA+成纤维细胞位于更深、胶原密集区域。
- 在霉酚酸酯使用者中,高CD34和高α-SMA预测早期SSc的改善;然而,高α-SMA预测晚期SSc改善几率较低。
- 早期SSc中α-SMA低/CD34低免疫表型及晚期SSc中α-SMA高者改善概率最低。
- 在晚期SSc中,α-SMA高者皮肤B细胞高于α-SMA低者。
关键数值与推荐
- 早期疾病定义为病程<18个月,晚期疾病定义为病程≥18个月。
- 临床改善定义为52周时mRSS下降>5分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the relationship of skin fibroblast CD34 and α-smooth muscle actin (α-SMA) and immune cell infiltration with disease duration in diffuse cutaneous systemic sclerosis (dcSSc) and identify predictors of improvement. METHODS: Skin biopsies and clinical data were analyzed from patients with dcSSc enrolled in lenabasum (n = 79), belimumab (n = 18), or nilotinib (n = 8) trials. CD34 and α-SMA were scored semiquantitatively. Immune cells (CD20+, CD3+, and CD123+) were counted. Clinical and histologic features were compared between those with early (<18 months) versus later disease (≥18 months). Clinical improvement was defined as >5-point decrease in modified Rodnan skin score (mRSS) at 52 weeks. An Akaike's information criterion-optimal multiple logistic regression model for clinical improvement among 68 mycophenolate mofetil (MMF) users was developed. Fibroblast spatial organization was visualized using imaging mass cytometry (IMC) in a representative sample. RESULTS: Despite similar baseline mRSS, early disease was associated with lower CD34, higher α-SMA, increased B cells, and greater mRSS improvement compared with later SSc. IMC demonstrated regions of CD34+ fibroblasts in superficial dermis and α-SMA+ fibroblasts in deeper, collagen-dense regions. Among MMF users, high CD34 and α-SMA predicted improvement in early SSc; however, high α-SMA predicted lower odds of improvement in later SSc. The probability of improvement was lowest in early SSc with α-SMAlow/CD34low immunophenotype and later SSc with α-SMAhigh. In later SSc, B cells were higher in α-SMAhigh versus α-SMAlow skin. CONCLUSION: Fibroblast immunophenotype varied by baseline disease duration and improved model performance for identifying those with improvement on MMF. Skin biopsies may be useful for refining prognosis and guiding patient management decisions.
引用
- Lakin KS, Spivack J, Gordon JK, et al. Skin Biopsies Enhance Prediction of Clinical Trajectory in Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2025. PMID: 40888138. doi:10.1002/art.43370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。